8-K
filed December 22, 2022, 6:59 PM ET
ticker MTVA
CIK 0001638287
other material
confidence high
sentiment neutral
materiality 0.50
NeuroBo shareholders approve 2022 equity plan; authorize share issuance to Dong-A ST
MetaVia Inc.
- Stockholders approved the 2022 Equity Incentive Plan with 362,390 votes for and 10,863 against.
- Plan reserve: 4,910,073 shares plus prior plan shares; annual 5% of fully diluted shares through 2027.
- Approved issuance of common shares to Dong-A ST under license and securities purchase agreements, including on conversion of Series A Preferred and warrant exercise.
- Special meeting also approved issuance of shares upon exercise of Series A/B Warrants from Nov. 2022 offering.
- Following conversion of Series A Preferred, 18,972,026 common shares outstanding.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
MetaVia Inc. shareholders approved Approval of issuance of shares in connection with License Agreement and Securities Purchase Agreement at the 2022-12-22 meeting.
- Outcome
- passed
- Meeting
- 2022-12-22
Exact text from the filing
Proposal 1— Approval, in accordance with applicable Nasdaq rules, of the issuance of shares of common stock in respect of the License Agreement, and pursuant to the Securities Purchase Agreement, including upon the conversion of shares of the Company’s Series A Convertible Preferred Stock issued to Dong-A pursuant to the terms and conditions of the License Agreement and the Securities Purchase Agreement, the exercise of warrants issued to Dong-A pursuant to the terms and conditions of the Securities Purchase Agreement and in respect of various commercial and regulatory milestone payments that may become payable in the future to Dong-A under the terms and conditions of the License Agreement that the Company may elect to pay to Dong-A in shares of the Company’s common stock Votes For Votes Against Votes Abstain 366,971 6,112 1,883
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
MetaVia Inc. shareholders approved Approval of issuance of shares upon exercise of Series A and Series B Warrants at the 2022-12-22 meeting.
- Outcome
- passed
- Meeting
- 2022-12-22
Exact text from the filing
Proposal 2— Approval pursuant to Nasdaq Listing Rule 5635(d) and Nasdaq’s interpretations and guidance thereunder, the issuance of shares of the Company’s common stock upon the exercise of the Company’s Series A Warrants and Series B Warrants issued to investors in the Company’s underwritten offering that closed on November 8, 2022 Votes For Votes Against Votes Abstain 365,882 7,416 1,668
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
MetaVia Inc. shareholders approved Approval of the NeuroBo Pharmaceuticals, Inc. 2022 Equity Incentive Plan at the 2022-12-22 meeting.
- Proposal
- equity plan
- Outcome
- passed
- Meeting
- 2022-12-22
Exact text from the filing
Proposal 3— Approval of the NeuroBo Pharmaceuticals, Inc. 2022 Equity Incentive Plan Votes For Votes Against Votes Abstain 362,390 10,863 1,713
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
MetaVia Inc. shareholders approved Authorization of adjournments of the Special Meeting at the 2022-12-22 meeting.
- Outcome
- passed
- Meeting
- 2022-12-22
Exact text from the filing
Proposal 4—Authorization of one or more adjournments of the Special Meeting to solicit additional proxies in the event there are insufficient votes to approve Proposals 1, 2 or 3 Votes For Votes Against Votes Abstain 362,373 10,891 1,702
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.